Benzinga's Top #PreMarket Gainers
PTC Therapeutics, Inc. (NASDAQ: PTCT) shares climbed 13.42 percent to $36.00 in pre-market trading after the company reported results from the Phase 3 ACT DMD clinical trial of Translarna™ (ataluren) in patients with Duchenne muscular dystrophy. Barclays' Geoffrey Meacham maintained an Overweight rating on the company, with a price target of $100.
Weibo Corp (ADR) (NASDAQ: WB) shares surged 7.43 percent to $14.75 in pre-market trading after gaining 4.97 percent on Thursday.
Orexigen Therapeutics, Inc. (NASDAQ: OREX) gained 6.01 percent to $3.00 in pre-market trading after jumping 15.51 percent on Thursday.
SunTrust Banks, Inc. (NYSE: STI) shares rose 2.53 percent to $40.52 in pre-market trading after the bank reported stronger-than-expected earnings for the third quarter.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.